 | Up a level |
2016
Krug, U., Berdel, W. E., Gale, R. P., Haferlach, C., Schnittger, S., Mueller-Tidow, C., Braess, J., Spiekermann, K., Staib, P., Beelen, D., Serve, H., Schliemann, C., Stelljes, M., Balleisen, L., Maschmeyer, G., Grueneisen, A., Eimermacher, H., Giagounidis, A., Rasche, H., Hehlmann, R., Lengfelder, E., Thiel, E., Reichle, A., Aul, C., Ludwig, W-D, Kern, W., Haferlach, T., Koepcke, W., Goerlich, D., Sauerland, M. C., Heinecke, A., Woermann, B. J., Hiddemann, W. and Buechner, T. (2016). Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia, 30 (6). S. 1230 - 1237. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
2015
Einsele, H., Vogel, M., Mueller, J., Knop, S., Kropff, M., Langer, C., Sayer, H., Jung, W., Wandt, H., Bassermann, F., Gramatzki, M., Roesler, W., Brugger, W., Engelhardt, M., Fischer, T., Giagounidis, A., Heidemann, E., Kroeger, N., Sezer, O., Bentz, M., Pfreundschuh, M., Salwender, H., Ludwig, W. -D., Roellig, C., Staib, P., Runde, V., Scheid, C., Ostermann, H., Hess, G., Hebart, H., Repp, R., Hart, C., Frickhofen, N., Straka, C. and Pflueger, K. -H. (2015). RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). Haematologica, 100. S. 151 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E. and Mueller-Tidow, C. (2015). DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy. Oncol. Res. Treat., 38. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262